Core Viewpoint - North Chip Life (688712.SH) is a national high-tech enterprise focused on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, aiming to revolutionize solutions in this field [1] Group 1: Company Overview - North Chip Life has developed a total of 11 products and has 6 products under research, covering five major categories: IVUS systems, FFR systems, vascular access products, shockwave balloon therapy systems, and electrophysiological solutions [6] - The core product, the IVUS system, is China's first domestically innovated 60MHz high-definition and high-speed IVUS product, recognized for its high-definition, high-speed, and intelligent features [6] - The FFR system, another core product, is considered the gold standard for guiding PCI treatment and diagnosing myocardial ischemia, receiving high-level recommendations from various domestic and international guidelines [6] Group 2: Intellectual Property and Recognition - As of June 30, 2025, North Chip Life holds 185 authorized patents domestically and internationally, including 86 invention patents and 14 PCT international patent applications [7] - The company has received multiple recognitions, including being designated as a "Guangdong Province High-Performance Cardiovascular Intervention Precision Diagnosis and Treatment Engineering Technology Research Center" and a "National Specialized and Innovative 'Little Giant' Enterprise" [7] Group 3: Market and Sales Dynamics - The company faces a high customer concentration risk, with sales to the top five customers accounting for 82.06%, 62.28%, and 74.21% of its main business revenue from 2022 to 2024 [7] - The company is in the early stages of product commercialization, primarily selling through domestic and international distributors [7] Group 4: R&D Risks - There are inherent risks in the research and development of innovative interventional medical devices for cardiovascular diseases, with uncertainties regarding the successful industrialization of research outcomes [8] - Factors such as team changes, insufficient funding, and failures in research validation or clinical trials could hinder the development of new products [8]

4月21日，惠泰医疗今日收盘438.5元，上涨1.31%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到63.21倍，总市值425.70亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均47.69倍，行业中值29.88倍，惠泰医疗排 名第97位。 截至2024年三季报，共有40家机构持仓惠泰医疗，其中基金40家，合计持股数471.21万股，持股市值 18.25亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)97惠泰医疗63.2163.2117.83425.70亿行业平均 47.6950.834.76102.51亿行业中值29.8830.502.3545.38亿1天益医疗-2712.97-2712.971.7020.18亿2硕世生 物-1868.25-1868.251.1537.40亿3诺唯赞-536.80-536.802.4697.13亿4澳华内镜-516.11258.864.1354.39亿5博 晖创新-360.85-222.173.9855.39亿6康泰医学-265.2731.122.7151.59亿7华大基因-198.26216.862.05201.47亿 8奥精 ...